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Serum total homocysteine concentration before and after renal
transplantation.
Background. Hyperhomocysteinemia is by now an established
risk factor for the development of atherosclerosis. Total homo-
cysteine concentration (tHcy) correlates inversely with glomerular
filtration rate, and it is roughly three times as high in hemodialysis
patients as in healthy individuals. Therefore, tHcy would be
expected to fall markedly after successful renal transplantation.
The aim of the present study was to assess the changes in tHcy
associated with renal transplantation.
Methods. tHcy was analyzed in samples collected before renal
transplantation and at six months after transplantation in 55 stable
patients, all of whom were treated with cyclosporine (CS). tHcy
was also analyzed in samples from 55 controls characterized by
markers of renal function that matched those of the post-
transplant state.
Results. At six months after transplantation, tHcy was signifi-
cantly decreased as compared with pretransplant tHcy (27.7 6
14.8 vs. 36.9 6 21.3 mmol/liter, P , 0.001). Post-transplant tHcy
was markedly higher than the tHcy of the control group (27.7 6
14.8 vs. 16.0 6 5.3 mmol/liter, P , 0.0001). The post-transplant
change in tHcy ranged widely, the average change being a
reduction of 14%. Sixteen patients (29%) actually manifested an
increase in post-transplant tHcy. The post-transplant changes in
tHcy correlated inversely with pretransplant tHcy (r 5 20.66, P ,
0.0001) and directly with the changes in serum albumin concen-
trations (r 5 0.35, P , 0.05) and CS trough concentrations (r 5
0.29, P , 0.05). A multivariate analysis, including the post-
transplant changes in serum concentrations of folate and albumin
as well as creatinine clearances explained 21% of the change in
tHcy (P , 0.05). After inclusion of the CS concentration, an
independent predictor, the model accounted for 28% of the
post-transplant change in tHcy (P , 0.01).
Conclusion. The post-transplant reduction in tHcy was far
smaller than expected with respect to renal function, and the
post-transplant changes in the major biochemical determinants of
tHcy contributed relatively little to explain the change in tHcy.
Thus, the results suggest the post-transplant introduction of one
or more factors that induce an increase in tHcy. Treatment with
CS appears to be such a factor.
Hyperhomocysteinemia is an independent risk factor for
the development of atherosclerosis according to a few large
prospective investigations [1, 2] and many small retrospec-
tive studies [3, 4]. The mechanism behind the vascular
damage has not been established with certainty, but there is
evidence of explanatory factors such as direct endothelial
toxicity as well as functional disturbances of platelets and
coagulation factors [3]. Hyperhomocysteinemia is fre-
quently observed in patients with renal insufficiency [5],
which is of interest due to the greatly increased mortality in
complications to atherosclerosis in this patient category [6].
Homocysteine metabolism in renal failure has been the
subject of many investigations [5]. Plasma total homocys-
teine concentration (tHcy) is significantly increased early in
renal insufficiency [7] and dialysis patients manifest about
threefold increase in tHcy as compared with healthy indi-
viduals [5]. The mechanisms behind the hyperhomocys-
teinemia of uremia have not been fully elucidated, but
homocysteine removal may be hampered by reduced net
renal uptake [8] and possibly enzyme inhibition [5]. On the
other hand, relatively little is known about homocysteine
metabolism in renal transplant recipients. Homocysteine
concentration was increased in two studies of renal trans-
plant recipients most of which were treated with azathio-
prine and prednisolone [9, 10]. In one study, tHcy was
higher in cyclosporine-treated renal transplant recipients
than in patients on azathioprine and prednisolone only,
renal function being similar in the study groups [11].
The purpose of the present study was to assess the
changes in tHcy associated with renal transplantation in
patients treated with cyclosporine (CS).
METHODS
Patients
The renal transplant recipients were consecutively re-
cruited at the Transplant Unit of the University Hospital in
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Uppsala, Sweden. Included in the study were the 55 stable
patients who were available for blood sampling six months
after transplantation. Demographic data are given in Table
1. Eight patients received a kidney from a living donor.
Forty-three had a primary transplantation. The causes of
end-stage renal disease were chronic glomerulonephritis
(N 5 24), diabetic nephropathy (N 5 8), chronic interstitial
nephritis (N 5 6), polycystic kidney disease (N 5 6),
nephrosclerosis (N 5 5), and unspecified renal disease
(N 5 6). At the time of transplantation, 49 patients were on
chronic hemodialysis and 6 patients on continuous perito-
neal dialysis. The dialysis patients were generally pre-
scribed low-dose folic acid substitution (0.3 mg daily). A
subgroup of 14 patients was taking folic acid in pharmaco-
logical doses explaining the high mean serum folate con-
centration (Table 1).
The immunosuppressive protocol consisted of CS, aza-
thioprine and prednisolone according to the Scandinavian
Multicenter Trial protocol [12]. The doses of the immuno-
suppressive drugs are shown in Table 1.
In addition, 55 non-nephrotic patients were recruited for
control purposes (Table 1).
Procedure
Fasting blood samples were collected immediately before
transplantation and at six months after transplantation.
Serum was stored at 220°C for analysis of tHcy in the same
series.
Before and at six months after transplantation, serum
folate and albumin concentrations were analyzed. At six
months after transplantation, serum creatinine concentra-
tion, endogenous creatinine clearance and trough CS con-
centration in whole blood were also determined.
The control group was selected to match post-transplant
markers of renal function. Blood samples for analysis of
tHcy were collected as described above. Serum folate,
albumin and creatinine concentrations as well as creatinine
clearances were also measured.
Laboratory investigations
tHcy was measured by high performance liquid chroma-
tography after the reduction of disulfide-bonds by dithio-
threitol [13].
Serum creatinine concentration was analyzed by an
enzymatic method and endogenous creatinine clearance
was calculated after a 24-hour urine collection.
Trough CS concentration in whole blood was measured
by a radioimmunoassay with monoclonal antibodies (Cyclo-
Trac; Incstar Corporation, Stillwater, MN, USA).
Serum albumin concentration was analyzed by the bro-
mocresol green method and serum folate concentration by
a radioimmunoassay.
Statistics
The data are presented as mean 6 SD. Due to the skewed
distribution of tHcy values nonparametric statistical meth-
ods were used; pre- and post-transplant variables were
compared by the Wilcoxon’s rank order test for the paired
case, post-transplant and control variables were compared
by the Mann-Whitney U-test and correlation analyses were
performed with the Spearman’s rank correlation test. Mul-
tiple regression analyses were performed to identify inde-
pendent predictors of tHcy. Before inclusion into the
multivariate analyses, tHcy was log transformed.
RESULTS
Serum concentrations of folate, albumin and creatinine,
trough CS concentrations in whole blood, and endogenous
creatinine clearances are shown in Table 1.
Mean pretransplant tHcy was significantly higher than
mean post-transplant tHcy (36.9 6 21.3 vs. 27.7 6 14.8
mmol/liter, P , 0.001). The mean change was a reduction in
tHcy of 14% but the changes ranged from a reduction of
85% to an increase of 142%. Mean post-transplant tHcy
was significantly higher than mean tHcy of the renal
function matched control group (27.7 6 14.8 vs. 16.0 6 5.3
mmol/liter, P , 0.0001).
There were significant correlations between pretrans-
plant tHcy and post-transplant tHcy (r 5 0.42, P , 0.01;
Fig. 1), folate concentrations (r 5 20.38, P , 0.01), and
albumin concentrations (r 5 0.43, P , 0.01).
Post-transtrant tHcy correlated significantly with folate
concentrations (r 5 20.28, P , 0.05), creatinine concen-
trations (r 5 0.45, P , 0.01) and creatinine clearances (r 5
20.42, P , 0.01) but not with albumin concentrations, CS
concentrations or the doses of CS, prednisolone and aza-
thioprine.
A multiple regression analysis, including folate and albu-
min concentrations as well as creatinine clearances, re-
vealed that these variables only explained 23% of post-
transplant tHcy (P , 0.05) whereas the same variables
Table 1. Characteristics of renal transplant recipients before
(pretransplant) and at six months after transplantation (post-transplant)
as well as those of renal function-matched controls
Pretransplant Post-transplant Controls
Age years 46 6 15 — 51 6 16
Sex (M/F) 25/30 — 28/27
Serum creatinine
mmol/liter
— 149 6 57 144 6 86
Creatinine clearance
ml/min
— 51 6 21 52 6 16
Serum albumin g/liter 41 6 5 40 6 4 38 6 4
Serum folate nmol/liter 44 6 61 12 6 12 15 6 5
B-cyclosporine
mmol/liter
— 137 6 56 —
Cyclosporine dose
mg/kg/day
— 4.2 6 1.4 —
Prednisolone dose
mg/kg/day
— 0.14 6 0.04 —
Azathioprine dose
mg/kg/day
— 1.25 6 0.62 —
Data are given as mean 6 standard deviation.
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explained 65% of tHcy in the renal function-matched
controls (P , 0.0001).
The post-transplant changes in tHcy correlated inversely
with pretransplant tHcy (r 5 20.66, P , 0.0001), that is,
lower post-transplant tHcy values were associated with less
post-transplant reductions. The post-transplant changes in
tHcy correlated also with the changes in albumin concen-
trations (r 5 0.35, P , 0.05) and CS concentrations (r 5
0.29, P , 0.05; Fig. 2), but not with the changes in folate
concentrations, the creatinine clearances or with the doses
of CS, prednisolone and azathioprine.
A multiple regression analysis showed that the post-
transplant changes in folate (r 5 20.13, NS) and albumin
concentrations (r 5 0.44, P , 0.01) as well as the creatinine
clearances (r 5 20.27, P 5 0.06) accounted for 21% (P ,
0.05) of the post-transplant changes in tHcy. The model
explained 28% (P , 0.01) after the inclusion of CS
concentrations (r 5 0.30, P , 0.05).
tHcy increased in 16 patients (29%) after transplanta-
tion. These patients had significantly lower pretransplant
tHcy than the others (24.0 6 9.0 vs. 42.0 6 22.6 mmol/liter,
P , 0.001). Pre- and post-transplant folate and albumin
concentrations, creatinine clearances as well as pred-
nisolone and azathioprine doses did not differ between the
groups. However, these 16 patients were receiving higher
doses of CS (5.0 6 1.6 vs. 3.8 6 1.2 mg/kg, P , 0.01) and
had higher CS concentrations (169 6 70 vs. 124 6 43
mmol/liter, P , 0.05) than the others.
DISCUSSION
tHcy was significantly decreased six months after renal
transplantation as compared with pretransplant tHcy. How-
ever, numerically, the decrease was far smaller than ex-
pected with regard to renal function. This was illustrated by
the marked difference between the mean post-transplant
tHcy and the mean tHcy of the renal function-matched
control group.
Hyperhomocysteinemia is an established cardiovascular
risk factor, known to predict morbidity [4] as well as
mortality in the general population [14]. There is an inverse
correlation between glomerular filtration rate and tHcy [7]
and hyperhomocysteinemia is highly prevalent in dialysis
patients [5]. After successful transplantation renal function
is greatly improved and, therefore, a substantial decrease in
tHcy would be expected. This, in combination with the fact
that renal transplant recipients manifest a markedly in-
creased cardiovascular risk [6], calls for studies on post-
transplant homocysteine metabolism. A few reports have
shown increased tHcy in renal transplant recipients [10, 11,
15] and there is evidence that hyperhomocysteinemia is
associated with increased prevalence of atherosclerotic
complications in these patients [10, 11]. The purpose of the
present study was to document the changes in tHcy occur-
ring after renal transplantation. The time point of six
months post-transplant was chosen for sampling because by
then most patients have reached a stable phase.
The mean value of pretransplant tHcy in the present
study was similar to the tHcy reported by this and other
laboratories, in patients with end-stage renal failure [16,
17]. After transplantation, tHcy only fell by a mean of 14%.
This change was statistically significant but the post-trans-
plant tHcy was still much higher than anticipated or almost
twice the value in patients with similar function in native
Fig. 1. A scattergram showing the relationship between pre-and post-
transplant plasma total homocysteine concentrations (tHcy). The corre-
lation coefficient was 0.42 (P , 0.05).
Fig. 2. A scattergram showing the relationship between the cyclosporine
concentrations and the post-transplant changes in tHcy (DtHcy). The
correlation coefficient was 0.29 (P , 0.05).
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kidneys. In addition, in 29% of the renal transplant recip-
ients, tHcy actually increased after transplantation. A mul-
tiple regresssion analysis, including traditional biochemical
determinants of tHcy, surprisingly showed that the im-
provement in renal function only had a marginal influence
on the post-transplant change in tHcy and that the changes
in serum folate concentrations did not have a significant
predictive value. On the other hand, the CS concentrations
and the changes in serum albumin concentrations were
independent predictors of the post-transplant change in
tHcy. These results agree with the comparison between the
patients who manifested an increase in tHcy and those who
showed a decrease in tHcy after transplantation; the only
difference between the groups were higher CS concentra-
tions and CS doses as well as lower initial tHcy values in the
former group. The direct correlation between the pre- and
post-transplant concentrations of tHcy probably reflects the
genetic influence on homocysteine metabolism.
Not only was the post-transplant decrease in tHcy unex-
pectedly small, but changes in major determinants of tHcy
did not explain more than 21% of the post-transplant
change in tHcy. This is in accordance with a prospective
study of heart transplant recipients showing that a post-
transplant increase in tHcy of 70% could not be adequately
accounted for by changes in vitamin concentrations and
renal function [18]. Thus, the influence on homocysteine
metabolism after transplantation must be sought outside
the spectrum of the traditional determinants of tHcy.
Possibly, the renal graft does not compensate for all the
functions of healthy kidneys or the dialysis treatment and
the associated drug treatment may play a role in the
context. However, this would not account for the fact that
the influence on homocysteine metabolism seems to be
similar after heart transplantation and renal transplanta-
tion. Therefore, the post-transplant introduction of a factor
that influences homocysteine metabolism seems more
likely. Conceivably, consequences of immunological reac-
tions or side effects of immunosuppressant(s) are involved.
The present study shows an independent relationship be-
tween CS concentrations and the post-transplant changes
in tHcy. Moreover, in a previous investigation we found
that CS-treated renal transplant recipients had significantly
higher tHcy than those treated with azathioprine and
prednisolone only [11]. In that study, there was no corre-
lation between tHcy and folate concentrations in the CS-
treated patients, suggesting an effect on the folate-depen-
dent remethylation of homocysteine. This hypothesis is
supported by the present finding that the changes in serum
folate concentrations did not significantly predict the post-
transplant change in tHcy. Even though trough CS concen-
tration is taken into consideration, much of the post-
transplant change in tHcy is still unaccounted for. For this
purpose, the area under the CS curve may be a better
determinant than CS trough concentration, or the other
immunosuppressants may play a role. However, in the
present study, no relationship could be found between tHcy
and either prednisolone doses or azathioprine doses.
Treatment with 5 to 16 mg of folic acid daily lowers tHcy
in practically all hemodialysis patients, resulting in a mean
decrease in tHcy of about 30 to 50% [16, 17]. In the present
study, the change in tHcy varied widely after transplanta-
tion, the mean change being a reduction of 14%. Thus, it
seems that folic acid administered in high dosage to dialysis
patients is a more reliable tHcy-lowering treatment than
renal transplantation. However, the present study was
limited to one time point after transplantation, that is, six
months. Future studies should cover a wider range of time
in order to document the natural history of homocysteine-
mia in this group of patients. In this context, it should be
mentioned that high-dose treatment with folic acid also
lowers tHcy effectively in cyclosporine-treated renal trans-
plant recipients [19].
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